Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial.

Studied

A randomized, double-blind, placebo-controlled phase two substudy tested once-weekly retatrutide for reducing liver fat.

Who / model

Participants had metabolic dysfunction-associated steatotic liver disease and at least ten percent liver fat.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Retatrutide produced dose-related liver-fat reductions versus placebo, and more participants reached normal liver-fat levels at higher doses.

Limits

This was a substudy of ninety-eight selected participants rather than a standalone broad liver-disease trial.

Read summary source ↗ · Prepared 9/16/2026 · AI-assisted, source-based summary